Skip to main content
editorial
. 2024 Sep;19(3):519–525. doi: 10.26574/maedica.2024.19.3.519

FIGURE 2.

FIGURE 2.

Variations in prevalence of glomerulopathies during the studied period (*: p<0,05; CGN: crescentic glomerulonephritis; DN: diabetic nephropathy; EPGN: diffuse endocapillary proliferative glomerulonephritis; FSGS: focal and segmental glomerulosclerosis; HGP: hereditary glomerulopathies; IgAN: IgA nephropathy; LN: lupus nephritis; MCD: minimal change disease; MN: membranous nephropathy; MPGN: membranoproliferative glomerulonephritis; Others = monoclonal immunoglobulin deposition disease, fibrillary glomerulonephritis, thrombotic microangiopathy; RA: renal amyloidosis).